Equities research analysts at B. Riley started coverage on shares of TG Therapeutics (NASDAQ:TGTX) in a research report issued to clients and investors on Friday. The brokerage set a “buy” rating and a $21.50 price target on the biopharmaceutical company’s stock. B. Riley’s price target points to a potential upside of 150.00% from the company’s previous close.
TGTX has been the topic of a number of other reports. Zacks Investment Research downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. BidaskClub lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. SunTrust Banks restated a “buy” rating and set a $28.00 target price on shares of TG Therapeutics in a report on Tuesday, October 3rd. ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Finally, HC Wainwright restated a “buy” rating and set a $33.00 target price (up previously from $18.00) on shares of TG Therapeutics in a report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $26.25.
Shares of TG Therapeutics (NASDAQ TGTX) opened at $8.60 on Friday. TG Therapeutics has a fifty-two week low of $4.10 and a fifty-two week high of $15.35.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc boosted its stake in shares of TG Therapeutics by 4.1% during the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 384 shares in the last quarter. BB&T Securities LLC purchased a new position in TG Therapeutics in the 1st quarter valued at about $121,000. Hollencrest Securities LLC purchased a new position in TG Therapeutics in the 2nd quarter valued at about $121,000. Thompson Davis & CO. Inc. purchased a new position in TG Therapeutics in the 1st quarter valued at about $154,000. Finally, Bank of America Corp DE lifted its stake in TG Therapeutics by 11.0% in the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 1,395 shares in the last quarter. 50.45% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “TG Therapeutics (TGTX) Receives New Coverage from Analysts at B. Riley” was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/01/tg-therapeutics-tgtx-receives-new-coverage-from-analysts-at-b-riley.html.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.